Jane Street’s Acadia Pharmaceuticals ACAD Stock Holding History

Jane Street’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$868K	Buy	39,000 +21,700	+125%	+$519K	﹤0.01%	6826
2025 Q4	$462K	Sell	17,300 -7,800	-31%	-$186K	﹤0.01%	7882
2025 Q3	$536K	Sell	25,100 -28,500	-53%	-$674K	﹤0.01%	7712
2025 Q2	$1.16M	Buy	53,600 +38,200	+248%	+$710K	﹤0.01%	5344
2025 Q1	$256K	Sell	15,400 -22,300	-59%	-$405K	﹤0.01%	8071
2024 Q4	$692K	Buy	+37,700	New	+$608K	﹤0.01%	6094
2024 Q2	–	Sell	-53,800	Closed	-$995K	–	9237
2024 Q1	$995K	Buy	53,800 +25,300	+89%	+$627K	﹤0.01%	5424
2023 Q4	$892K	Sell	28,500 -19,300	-40%	-$461K	﹤0.01%	5750
2023 Q3	$996K	Buy	+47,800	New	+$1.3M	﹤0.01%	5189
2023 Q2	–	Sell	-41,300	Closed	-$777K	–	8585
2023 Q1	$777K	Sell	41,300 -2,500	-6%	-$47.6K	﹤0.01%	5498
2022 Q4	$697K	Buy	43,800 +11,400	+35%	+$178K	﹤0.01%	5582
2022 Q3	$530K	Sell	32,400 -70,200	-68%	-$1.14M	﹤0.01%	6594
2022 Q2	$1.45M	Buy	102,600 +24,500	+31%	+$457K	﹤0.01%	4778
2022 Q1	$1.89M	Sell	78,100 -137,900	-64%	-$3.34M	﹤0.01%	4864
2021 Q4	$5.04M	Buy	216,000 +179,700	+495%	+$3.61M	﹤0.01%	2844
2021 Q3	$603K	Sell	36,300 -87,400	-71%	-$1.68M	﹤0.01%	6916
2021 Q2	$3.02M	Buy	123,700 +52,700	+74%	+$1.19M	﹤0.01%	3557
2021 Q1	$1.83M	Buy	71,000 +27,600	+64%	+$1.22M	﹤0.01%	4180
2020 Q4	$2.32M	Sell	43,400 -3,600	-8%	-$179K	﹤0.01%	3237
2020 Q3	$1.94M	Buy	47,000 +24,400	+108%	+$1.05M	﹤0.01%	3092
2020 Q2	$1.09M	Sell	22,600 -22,700	-50%	-$1.09M	﹤0.01%	3930
2020 Q1	$1.91M	Buy	45,300 +31,000	+217%	+$1.28M	﹤0.01%	2068
2019 Q4	$612K	Sell	14,300 -7,800	-35%	-$339K	﹤0.01%	3432
2019 Q3	$795K	Buy	22,100 +1,600	+8%	+$48.5K	﹤0.01%	2920
2019 Q2	$548K	Sell	20,500 -8,000	-28%	-$204K	﹤0.01%	3469
2019 Q1	$765K	Buy	+28,500	New	+$666K	﹤0.01%	3143
2018 Q4	–	Sell	-17,500	Closed	-$363K	–	4847
2018 Q3	$363K	Sell	17,500 -12,600	-42%	-$198K	﹤0.01%	3980
2018 Q2	$460K	Buy	30,100 +18,600	+162%	+$332K	﹤0.01%	3666
2018 Q1	$258K	Sell	11,500 -2,200	-16%	-$60.9K	﹤0.01%	4193
2017 Q4	$413K	Buy	+13,700	New	+$438K	﹤0.01%	3393
2017 Q3	–	Sell	-11,800	Closed	-$329K	–	4370
2017 Q2	$329K	Sell	11,800 -8,600	-42%	-$256K	﹤0.01%	3505
2017 Q1	$701K	Sell	20,400 -85,000	-81%	-$3M	﹤0.01%	2495
2016 Q4	$3.04M	Buy	+105,400	New	+$2.79M	0.01%	990
2016 Q3	–	Sell	-10,500	Closed	-$341K	–	3926
2016 Q2	$341K	Sell	10,500 -102,700	-91%	-$3.44M	﹤0.01%	3179
2016 Q1	$3.17M	Buy	113,200 +97,000	+599%	+$2.12M	0.02%	833
2015 Q4	$578K	Buy	+16,200	New	+$571K	﹤0.01%	2324
2015 Q3	–	Sell	-5,000	Closed	-$209K	–	3495
2015 Q2	$209K	Sell	5,000 -7,800	-61%	-$302K	﹤0.01%	3233
2015 Q1	$417K	Buy	+12,800	New	+$440K	﹤0.01%	2218

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Jane Street's ACAD Position: Q1 2026 in Review

Jane Street opened a new position in Acadia Pharmaceuticals (ACAD) in Q1 2026: 803,265 shares worth $17.9M. The stake represents ﹤0.01% of the portfolio and ranks #1883 among its holdings. This is a return to the name: Jane Street previously reported a position in ACAD as recently as Q3 2025.

Jane Street first reported a position in ACAD in Q3 2013 and has held it in 40 quarters since. 341 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

Jane Street held 803,265 shares of Acadia Pharmaceuticals worth $17.9M as of Q1 2026.
Acadia Pharmaceuticals was a new Jane Street position in Q1 2026.
Acadia Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #1883 holding.
Jane Street first reported a position in Acadia Pharmaceuticals in Q3 2013 and has held it in 40 quarters since.
341 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.